The companies have combined technology to create a broad family of issued patents and products to help identify bed bug infestations.
FRANKLIN, Mass. — ZeptoMetrix Corporation (ZMC), a fully integrated biotechnology company specializing in sensitive Diagnostic Test Development and CytoSignet, a leader in the development, commercialization and licensing of Intellectual Property for biochemical detection, have established an exclusive partnership for the development of a broad family of issued patents and products to help identify bed bug infestations.
Bed Bugs feed only on blood throughout their lifespan. After feeding, the parasite seeks harborage to digest, defecate and wait for the next feeding opportunity. It is during its movement to and from hiding places the insect leaves a biochemical trail including fecal matter as evidence of its presence and passage. Hemoglobin and various other biochemical markers are left scattered in the environment providing valuable and readily obtainable footprints of their activities and locations. This partnership combined technology and has resulted in multiple patented testing systems taking advantage of the debris left by the insect announcing its existence.
Together, this collaboration is an ongoing initiative to provide simple, cost effective and accurate answers to the global Bed Bug Infestation through a better use of science.
The new product line includes:
Detection Spray – Bed BugDetect 1
A simple to prepare atomized spray; easily dispensed with hand-held bottle; cost effective; non-toxic; immediate and enhanced visualization of bed bug movement.
On-Site Screening Capabilities – Bed BugDetect 2
A highly sensitive screening test; low cost design; simple and unobtrusive to implement; designed for on-site results by property owners, operation managers and other various, untrained, non-licensed personnel to indicate that blood-feeding on humans has occurred.
Confirmation Tests – Bed BugDetect 3
Debris is collected and analyzed for specific Bed Bug biochemicals including DNA, test can be performed with or without the Detection Spray or On-Site Screening Test.
The technologies discussed above are covered by US Patents No. 7,727,734 and 8,460,890; European Patent No. 1,920,239 B1; Canadian Patent No. 2,621,590 and other patents pending.
CURRENT NEWS UPDATE
*US Patents No. 7,727,734 and 8,460,890; European Patent No. 1,920,239 B1; Canadian Patent No. 2,621,590
ZeptoMetrix Corporation · 878 Main Street ·Buffalo, NY 14202 · Tel 716.882.0920 · 800.274.5487 · Fax 716.882.0959
For appropriate usage of our patented detection technology, Licensing Agreements are currently available and are being considered
For more information contact: ZeptoMetrix Corporation Michael Hershfield at 508/553-5852 or email@example.com